164 related articles for article (PubMed ID: 19952054)
1. Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer.
Kono T; Mamiya N; Chisato N; Ebisawa Y; Yamazaki H; Watari J; Yamamoto Y; Suzuki S; Asama T; Kamiya K
Evid Based Complement Alternat Med; 2011; 2011():418481. PubMed ID: 19952054
[TBL] [Abstract][Full Text] [Related]
2. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Kono T
Int J Clin Oncol; 2011 Aug; 16(4):322-7. PubMed ID: 21258836
[TBL] [Abstract][Full Text] [Related]
3. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Oki E; Emi Y; Kojima H; Higashijima J; Kato T; Miyake Y; Kon M; Ogata Y; Takahashi K; Ishida H; Saeki H; Sakaguchi Y; Yamanaka T; Kono T; Tomita N; Baba H; Shirabe K; Kakeji Y; Maehara Y
Int J Clin Oncol; 2015 Aug; 20(4):767-75. PubMed ID: 25627820
[TBL] [Abstract][Full Text] [Related]
4. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
[TBL] [Abstract][Full Text] [Related]
5. Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat.
Mizuno K; Kono T; Suzuki Y; Miyagi C; Omiya Y; Miyano K; Kase Y; Uezono Y
J Pharmacol Sci; 2014; 125(1):91-8. PubMed ID: 24784702
[TBL] [Abstract][Full Text] [Related]
6. An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi.
Mizuno K; Shibata K; Komatsu R; Omiya Y; Kase Y; Koizumi S
Cancer Biol Ther; 2016 Nov; 17(11):1206-1212. PubMed ID: 27416484
[TBL] [Abstract][Full Text] [Related]
7. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents.
Ushio S; Egashira N; Sada H; Kawashiri T; Shirahama M; Masuguchi K; Oishi R
Eur J Cancer; 2012 Jun; 48(9):1407-13. PubMed ID: 21907570
[TBL] [Abstract][Full Text] [Related]
8. Preventive effect of oral goshajinkigan on chronic oxaliplatin-induced hypoesthesia in rats.
Kono T; Suzuki Y; Mizuno K; Miyagi C; Omiya Y; Sekine H; Mizuhara Y; Miyano K; Kase Y; Uezono Y
Sci Rep; 2015 Nov; 5():16078. PubMed ID: 26542342
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
Yoshida N; Hosokawa T; Ishikawa T; Yagi N; Kokura S; Naito Y; Nakanishi M; Kokuba Y; Otsuji E; Kuroboshi H; Taniwaki M; Taguchi T; Hosoi H; Nakamura T; Miki T
J Oncol; 2013; 2013():139740. PubMed ID: 24307899
[TBL] [Abstract][Full Text] [Related]
10. [A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer].
Mamiya N; Kono T; Mamiya K; Satomi M; Chisato N; Ebisawa Y
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1295-7. PubMed ID: 17687217
[TBL] [Abstract][Full Text] [Related]
11. The Kampo medicine Goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel.
Abe H; Kawai Y; Mori T; Tomida K; Kubota Y; Umeda T; Tani T
Asian Pac J Cancer Prev; 2013; 14(11):6351-6. PubMed ID: 24377531
[TBL] [Abstract][Full Text] [Related]
12. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
Gamelin L; Boisdron-Celle M; Delva R; Guérin-Meyer V; Ifrah N; Morel A; Gamelin E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4055-61. PubMed ID: 15217938
[TBL] [Abstract][Full Text] [Related]
13. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.
Simpson D; Dunn C; Curran M; Goa KL
Drugs; 2003; 63(19):2127-56. PubMed ID: 12962525
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
Shimizu T; Satoh T; Tamura K; Ozaki T; Okamoto I; Fukuoka M; Nakagawa K
Int J Clin Oncol; 2007 Jun; 12(3):218-23. PubMed ID: 17566846
[TBL] [Abstract][Full Text] [Related]
16. Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study).
Kono T; Mishima H; Shimada M; Morita S; Sakamoto J;
Jpn J Clin Oncol; 2009 Dec; 39(12):847-9. PubMed ID: 19734172
[TBL] [Abstract][Full Text] [Related]
17. Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis.
Wen F; Zhou Y; Wang W; Hu QC; Liu YT; Zhang PF; Du ZD; Dai J; Li Q
Ann Oncol; 2013 Jan; 24(1):171-8. PubMed ID: 22898039
[TBL] [Abstract][Full Text] [Related]
18. [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].
Matsuda M; Matsusaka S; Kuboki Y; Itimura T; Ogura M; Suenaga M; Syouji D; Watanabe C; Chin K; Mizunuma N; Hatake K
Gan To Kagaku Ryoho; 2008 Mar; 35(3):461-6. PubMed ID: 18347395
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of oxaliplatin-associated neurotoxicity.
Grothey A
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
